| Recruiting | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+ Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia | Phase 3 | 2022-12-26 |
| Completed | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhi Alpha1-Antitrypsin Deficiency | Phase 1 / Phase 2 | 2021-08-13 |
| Terminated | A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpa COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection | Phase 3 | 2021-04-28 |
| Terminated | Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Partic COVID-19 | Phase 2 | 2021-01-29 |
| Completed | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dos Primary Immunodeficiency | Phase 4 | 2020-11-24 |
| Completed | Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medica COVID-19 | Phase 2 | 2020-09-17 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) Primary Immunodeficiency | Phase 3 | 2020-09-02 |
| Withdrawn | Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary I Primary Immunodeficiency | Phase 3 | 2019-12-01 |
| Terminated | Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Alb Acute-On-Chronic Liver Failure | Phase 3 | 2019-02-21 |
| Completed | Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites Decompensated Cirrhosis and Ascites | Phase 3 | 2018-07-24 |
| Terminated | Alphanate in Immune Tolerance Induction Therapy Hemophilia A, Congenital | Phase 2 | 2018-01-03 |
| Completed | Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) Anti-Hepatitis A Antibody Levels in Heathy Subjects | Phase 4 | 2017-10-31 |
| Completed | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis | Phase 2 | 2016-08-29 |
| Completed | Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participa Alpha1-Antitrypsin Deficiency | Phase 1 / Phase 2 | 2016-07-29 |
| Completed | Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficienc Alpha1-Antitrypsin Deficiency | Phase 1 / Phase 2 | 2016-07-29 |
| Completed | Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With C Congenital Afibrinogenemia | Phase 1 / Phase 2 | 2016-07-22 |
| Enrolling By Invitation | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Phase 3 | 2016-07-01 |
| Completed | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency Primary Immunodeficiency | Phase 3 | 2016-06-01 |
| Completed | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency Primary Immunodeficiency | Phase 3 | 2016-01-01 |
| Completed | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Grav Myasthenia Gravis, Generalized | Phase 2 | 2015-08-01 |
| Completed | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Myasthenia Gravis | Phase 2 | 2015-06-01 |
| Completed | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Myasthenia Gravis Exacerbations | Phase 3 | 2015-03-01 |
| Completed | A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin D Alpha₁-Antitrypsin Deficiency | Phase 2 / Phase 3 | 2014-10-01 |
| Completed | Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmon Cardiac Surgery, Cardiopulmonary Bypass | Phase 2 | 2014-06-26 |
| Terminated | Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus | Phase 2 | 2014-03-01 |
| Completed | An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Adm Rabies | Phase 1 | 2014-03-01 |
| Recruiting | Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patien Von Willebrand Disease | Phase 4 | 2013-12-01 |
| Active Not Recruiting | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pul Pulmonary Emphysema in Alpha-1 PI Deficiency | Phase 3 | 2013-11-01 |
| Completed | Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Proce Cystic Fibrosis | Phase 2 | 2012-08-01 |
| Completed | Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immuno Primary Immunodeficiency | Phase 4 | 2011-11-01 |
| Completed | A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion Acute Peripheral Arterial Occlusion | Phase 2 | 2010-12-01 |
| Completed | Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency Emphysema, Alpha 1-antitrypsin Deficiency (AATD) | Phase 2 | 2010-11-01 |
| Completed | A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Pati Acute Ischemic Stroke | Phase 1 / Phase 2 | 2009-11-01 |
| Completed | A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft O Arterial Occlusive Diseases | Phase 1 | 2007-03-01 |
| Terminated | Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Tetanus | Phase 4 | 2007-03-01 |
| Completed | A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency Immunologic Deficiency Syndrome | Phase 2 | 2006-11-01 |
| Completed | The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Defici Alpha 1-Antitrypsin Deficiency | Phase 3 | 2006-06-01 |
| Completed | Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficien Alpha 1-Antitrypsin Deficiency | Phase 3 | 2006-05-01 |
| Completed | Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 3 | 2004-04-01 |
| Completed | Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration Macular Degeneration | Phase 2 | 2004-01-01 |
| Completed | Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) Alpha 1-Antitrypsin Deficiency | Phase 2 | 2003-12-01 |
| Completed | Deposition of Inhaled Prolastin in Cystic Fibrosis Patients Cystic Fibrosis | Phase 2 | 2003-12-01 |
| Completed | Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP Purpura, Thrombocytopenic, Idiopathic | Phase 2 | 2003-07-01 |
| Completed | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting | Phase 2 | 2002-12-01 |
| Completed | Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency | Phase 3 | 2002-08-01 |